Abstract
We have previously reported early disease progression within 24 months (POD24) could be a surrogate marker for a substantially increased risk of death (2016 The Japanese Society of Hematology annual meeting). The aim of this study was to clarify clinical characteristics of DLBCL patients experiencing POD24 among lower International Prognostic Index (IPI) risk groups.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
